Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma’s Phase 1 Study of AP-101 for the Treatment of ALS
Library of Life
into transformative therapeutics.
Learning from the
Memory of Life
to develop truly novel therapies.
program for Parkinson in Phase 2.
antibody program for ALS
in Phase 1. Read more
Neurimmune is a biopharmaceutical company translating human immune memory into transformative therapeutics.
Neurimmune’s pipeline comprises drug candidates for Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, fronto-temporal dementia, dementia with Lewy bodies as well as cardiomyopathy and type 2 diabetes.
With its Reverse Translational Medicine™ technology platform, Neurimmune translates the genetic information obtained from white blood cells from elderly human donors into therapeutic antibodies.